Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action Mint crossover pilot study in reflux symptoms
2012-004109-28Phase 4Terminated
- Sponsor
- Reckitt
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Reckitt. Primary endpoint: Number of acid reflux events during first 24 hours. Started Dec 2012; status: terminated.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2012-004109-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004109-28.